Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Beder

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Annals of Hematology|February 11, 2026
Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trialLars Fransecky, Walter Fiedler, Christoph Röllig, et al.
Leukemia|November 21, 2022
Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)Sophie Steinhäuser, Patricia Silva, Lennart Lenk, et al.
Blood Cancer Journal|January 6, 2026
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemiaSophie Steinhäuser, Thomas Beder, Emely Hübner, et al.
Leukemia|April 10, 2022
UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatmentLorenz Bastian, Alina M Hartmann, Thomas Beder, et al.
Hemasphere|August 30, 2023
The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across AgeThomas Beder, Björn-Thore Hansen, Alina M Hartmann, et al.
Leukemia|May 14, 2024
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocolsMartin Neumann, Thomas Beder, Lorenz Bastian, et al.
Hemasphere|February 26, 2026
Intra-subtype heterogeneity shapes treatment response in <i>KMT2A</i>-rearranged ALL across all age groupsAlina M Hartmann, Lorenz Bastian, Malwine J Barz, et al.
Blood|March 27, 2026
IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy responseSonja Bendig, Alina M Hartmann, Wiebke Wessels, et al.
Blood|April 8, 2024
Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphomaEmma Kroeze, Ingram Iaccarino, Michelle M Kleisman, et al.
Blood|December 28, 2023
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALLLorenz Bastian, Thomas Beder, Malwine J Barz, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Annals of Hematology|February 11, 2026
Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trialLars Fransecky, Walter Fiedler, Christoph Röllig, et al.
Leukemia|November 21, 2022
Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)Sophie Steinhäuser, Patricia Silva, Lennart Lenk, et al.
Blood Cancer Journal|January 6, 2026
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemiaSophie Steinhäuser, Thomas Beder, Emely Hübner, et al.
Leukemia|April 10, 2022
UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatmentLorenz Bastian, Alina M Hartmann, Thomas Beder, et al.
Hemasphere|August 30, 2023
The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across AgeThomas Beder, Björn-Thore Hansen, Alina M Hartmann, et al.
Leukemia|May 14, 2024
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocolsMartin Neumann, Thomas Beder, Lorenz Bastian, et al.
Hemasphere|February 26, 2026
Intra-subtype heterogeneity shapes treatment response in <i>KMT2A</i>-rearranged ALL across all age groupsAlina M Hartmann, Lorenz Bastian, Malwine J Barz, et al.
Blood|March 27, 2026
IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy responseSonja Bendig, Alina M Hartmann, Wiebke Wessels, et al.
Blood|April 8, 2024
Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphomaEmma Kroeze, Ingram Iaccarino, Michelle M Kleisman, et al.
Blood|December 28, 2023
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALLLorenz Bastian, Thomas Beder, Malwine J Barz, et al.
Pageof 4